373O First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study
医学
贝伐单抗
化疗
宫颈癌
肿瘤科
临床研究阶段
内科学
癌症
作者
Nan Liu,Zijing Yang,Ding Tang,Hanmei Lou,Kai Zhang,Hui Cao,Dehui Zou,Xiaofeng Zhang,Song Xue,Xun Kang,Dong Wang